Cover Image

Graft preservation solution DuraGraft® alleviates vascular dysfunction following in vitro ischemia/reperfusion injury in rats

Vascular ischemia/reperfusion injury (IRI) in patients undergoing coronary artery bypass grafting can result in graft failure and the need for repeat revascularization procedures. DuraGraft® has been shown to protect structure and function in saphenous vein grafts against IRI. We compared the effect...

Full description

Saved in:
Bibliographic Details
Main Authors: Korkmaz-İçöz, Sevil (Author) , Ballikaya, Belinda (Author) , Soethoff, Jasmin (Author) , Kraft, Patricia (Author) , Sayour, Alex Ali (Author) , Radovits, Tamás (Author) , Loganathan, Sivakkanan (Author) , Karck, Matthias (Author) , Szabó, Gábor (Author) , Veres, Gábor (Author)
Format: Article (Journal)
Language:English
Published: 9 October 2021
In: Pharmaceuticals
Year: 2021, Volume: 14, Issue: 10, Pages: 1-9
ISSN:1424-8247
DOI:10.3390/ph14101028
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/ph14101028
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/1424-8247/14/10/1028
Get full text
Author Notes:Sevil Korkmaz-Icöz, Belinda Ballikaya, Jasmin Soethoff, Patricia Kraft, Alex Ali Sayour, Tamás Radovits, Sivakkanan Loganathan, Matthias Karck, Gábor Szabó and Gábor Veres
Description
Summary:Vascular ischemia/reperfusion injury (IRI) in patients undergoing coronary artery bypass grafting can result in graft failure and the need for repeat revascularization procedures. DuraGraft® has been shown to protect structure and function in saphenous vein grafts against IRI. We compared the effect of DuraGraft® to saline solution on arterial grafts submitted to IRI. Rat thoracic aortic rings were harvested and immediately mounted in organ bath chambers (control, n = 7 rats) or underwent cold ischemic preservation either in saline (IR, n = 9 rats) or DuraGraft® (IR+Dura, n = 9 rats). Vascular function was measured ex vivo and immunohistochemistry was performed. Impaired maximum vasorelaxation (Rmax) to ACh in the IR-group compared to controls was ameliorated by DuraGraft®, indicating an improvement in endothelial function (Rmax to ACh (%): IR + Dura 73 ± 2 vs. IR 48 ± 3, p < 0.05). Additionally, decreased aortic ring sensitivity to ACh (pD2-value: -log 50% maximum response) seen after IR in the saline group was increased by DuraGraft® (pD2 to ACh: IR+Dura 7.1 ± 0.1 vs. IR 6.3 ± 0.2, p < 0.05). Impaired maximum contractile response to phenylephrine and high potassium chloride concentrations in the IR group compared to controls was significantly improved by DuraGraft®. DuraGraft® alleviates vascular dysfunction following IRI by reducing nitro-oxidative stress and the expression of ICAM-1, without leukocytes engagement.
Item Description:Gesehen am 06.12.2021
Physical Description:Online Resource
ISSN:1424-8247
DOI:10.3390/ph14101028

Similar Items